STWX:SW:SW-SPDR® MSCI Europe Health Care UCITS ETF CHF (CHF)

ETF | Others |

Last Closing

USD 188.18

Change

+1.66 (+0.89)%

Market Cap

USD 0.66B

Volume

54.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

N/A

USD 1,244,681.59B
SPISI:SW UBS ETF (CH) - SPI® ESG (CHF)..

+0.02 (+0.10%)

USD 590,186.66B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.06 (+0.26%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.01 (+0.04%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

N/A

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-5.00 (-0.24%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-9.00 (-0.34%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.31 (+0.40%)

USD 131,872.43B

ETFs Containing STWX:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.04% 26% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.04% 26% F 27% F
Trailing 12 Months  
Capital Gain -14.11% 4% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.11% 4% F 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.51% 46% F 49% F
Dividend Return 4.51% 45% F 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.96% 63% D 67% D+
Risk Adjusted Return 64.78% 44% F 49% F
Market Capitalization 0.66B 62% D 58% F

Annual Financials (CHF)

Quarterly Financials (CHF)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.